{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T02:43:34Z","timestamp":1773283414525,"version":"3.50.1"},"reference-count":109,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,12,31]],"date-time":"2016-12-31T00:00:00Z","timestamp":1483142400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurolog\u00eda"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1016\/j.nrl.2015.03.005","type":"journal-article","created":{"date-parts":[[2015,5,11]],"date-time":"2015-05-11T21:28:01Z","timestamp":1431379681000},"page":"165-176","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"title":["Farmacogen\u00e9tica de reacciones adversas a f\u00e1rmacos antiepil\u00e9pticos"],"prefix":"10.1016","volume":"33","author":[{"given":"I.","family":"Fricke-Galindo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Jung-Cook","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"LLerena","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"L\u00f3pez-L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.nrl.2015.03.005_bib0550","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.33588\/rn.3911.2004276","article-title":"Farmacogen\u00f3mica: b\u00fasqueda de la terapia personalizada","volume":"39","author":"L\u00f3pez-L\u00f3pez","year":"2004","journal-title":"Rev Neurol."},{"key":"10.1016\/j.nrl.2015.03.005_bib0555","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/nrd705","article-title":"The genetic basis of variability in drug responses","volume":"1","author":"Roden","year":"2002","journal-title":"Nat Rev Drug Discov."},{"key":"10.1016\/j.nrl.2015.03.005_bib0560","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1001\/jama.279.15.1200","article-title":"Incidence of adverse drug reactions in hospitalized patients","volume":"279","author":"Lazarou","year":"1998","journal-title":"JAMA."},{"key":"10.1016\/j.nrl.2015.03.005_bib0565","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1136\/bmj.329.7456.15","article-title":"Adverse drug reactions as cause of admission to hospital: Prospective analysis of 18 820 patients","volume":"329","author":"Pirmohamed","year":"2004","journal-title":"BMJ."},{"key":"10.1016\/j.nrl.2015.03.005_bib0570","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1111\/j.1365-2125.2007.03064.x","article-title":"Incidence of fatal adverse drug reactions: A population based study","volume":"65","author":"Wester","year":"2007","journal-title":"Br J Clin Pharmacol."},{"key":"10.1016\/j.nrl.2015.03.005_bib0575","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1056\/NEJMsa1103053","article-title":"Emergency hospitalizations for adverse drug events in older americans","volume":"365","author":"Budnitz","year":"2011","journal-title":"N Engl J Med."},{"key":"10.1016\/j.nrl.2015.03.005_bib0580","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.curtheres.2008.04.005","article-title":"Cost evaluation of adverse drug reactions in hospitalized patients in Taiwan: A prospective, descriptive, observational study","volume":"69","author":"Chan","year":"2008","journal-title":"Curr Therap Res."},{"key":"10.1016\/j.nrl.2015.03.005_bib0585","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1136\/qshc.2004.010611","article-title":"Adverse drug events and medication errors: Detection and classification methods","volume":"13","author":"Morimoto","year":"2004","journal-title":"Qual Saf Health Care."},{"key":"10.1016\/j.nrl.2015.03.005_bib0590","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1345\/aph.10094","article-title":"Clinical an economic impact of adverse drug reactions in hospitalized patients","volume":"34","author":"Suh","year":"2000","journal-title":"Ann Pharmacother."},{"key":"10.1016\/j.nrl.2015.03.005_bib0595","first-page":"1","article-title":"International drug monitoring: The role of national centers Report of a WHO meeting","volume":"498","year":"1972","journal-title":"World Health Organ Tech Rep Ser."},{"key":"10.1016\/j.nrl.2015.03.005_bib0600","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/S0140-6736(00)02799-9","article-title":"Adverse drug reactions: Definitions, diagnosis, and management","volume":"356","author":"Edwards","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.nrl.2015.03.005_bib0605","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.mpaic.2011.04.010","article-title":"Adverse drug reactions","volume":"12","author":"Scott","year":"2011","journal-title":"Anaesth Intensive Care."},{"key":"10.1016\/j.nrl.2015.03.005_bib0610","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/S1474-4422(12)70153-9","article-title":"Adverse effects of antiepileptic drugs","volume":"11","author":"Perucca","year":"2012","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.nrl.2015.03.005_bib0615","doi-asserted-by":"crossref","first-page":"e2480","DOI":"10.1371\/journal.pntd.0002480","article-title":"Epilepsy and neurocysticercosis in Latin America: A systematic review and meta-analysis","volume":"7","author":"Bruno","year":"2013","journal-title":"PLos Negl Trop Dis."},{"key":"10.1016\/j.nrl.2015.03.005_bib0620","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1111\/j.1528-1167.2009.02481.x","article-title":"Estimation of the burden of active and life-time epilepsy: A meta-analytic approach","volume":"51","author":"Ngugi","year":"2010","journal-title":"Epilepsia."},{"key":"10.1016\/j.nrl.2015.03.005_bib0625","doi-asserted-by":"crossref","first-page":"161","DOI":"10.2165\/00003495-198020030-00001","article-title":"Clobazam. A review of its pharmacological properties and therapeutic use in anxiety","volume":"20","author":"Brogden","year":"1980","journal-title":"Drugs."},{"issue":"Suppl 2","key":"10.1016\/j.nrl.2015.03.005_bib0630","doi-asserted-by":"crossref","first-page":"S42","DOI":"10.1111\/j.1528-1157.2000.tb01523.x","article-title":"Adverse effects of antiepileptic drugs","volume":"41","author":"Greenwood","year":"2000","journal-title":"Epilepsia."},{"key":"10.1016\/j.nrl.2015.03.005_bib0635","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1111\/j.1528-1157.1988.tb04237.x","article-title":"Clinical side effects of phenobarbital, primidone, phenytoin, carbamazepine, and valproate during monotherapy in children","volume":"29","author":"Herranz","year":"1988","journal-title":"Epilepsia."},{"key":"10.1016\/j.nrl.2015.03.005_bib0640","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1586\/ern.10.57","article-title":"Teratogenic effects of antiepileptic drugs","volume":"10","author":"Hill","year":"2010","journal-title":"Expert Rev Neurother."},{"key":"10.1016\/j.nrl.2015.03.005_bib0645","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.yebeh.2012.03.023","article-title":"Patient reporting of suspected adverse drug reactions to antiepileptic drugs: Factors affecting attribution accuracy","volume":"24","author":"Jarernsiripornkul","year":"2012","journal-title":"Epilepsy Behav."},{"issue":"5 Suppl 2","key":"10.1016\/j.nrl.2015.03.005_bib0650","first-page":"S53","article-title":"Positive and negative psychiatric effects of antiepileptic drugs in patients with seizure disorders","volume":"53","author":"Ketter","year":"1999","journal-title":"Neurology."},{"key":"10.1016\/j.nrl.2015.03.005_bib0655","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.nrl.2013.02.013","article-title":"Post-authorisation study of eslicarbazepine as treatment for drug-resistant epilepsy: Preliminary results","volume":"29","author":"Massot","year":"2014","journal-title":"Neurolog\u00eda."},{"issue":"Suppl 3","key":"10.1016\/j.nrl.2015.03.005_bib0660","doi-asserted-by":"crossref","first-page":"S64","DOI":"10.1111\/j.1528-1157.1987.tb05780.x","article-title":"Carbamazepine side effects in children and adults","volume":"28","author":"Pellock","year":"1987","journal-title":"Epilepsia."},{"key":"10.1016\/j.nrl.2015.03.005_bib0665","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.seizure.2004.12.003","article-title":"A systematic review of treatment of typical absence seizures in children and adolescents with ethosuximide, sodium valproate or lamotrigine","volume":"14","author":"Posner","year":"2005","journal-title":"Seizure."},{"key":"10.1016\/j.nrl.2015.03.005_bib0670","first-page":"49","article-title":"Efectos teratog\u00e9nicos de f\u00e1rmacos antiepil\u00e9pticos","volume":"5","author":"Tomson","year":"2013","journal-title":"Neurol Arg."},{"key":"10.1016\/j.nrl.2015.03.005_bib0675","first-page":"3091","article-title":"Avances en el tratamiento de la epilepsia","volume":"10","author":"Riverol","year":"2009","journal-title":"Medicine."},{"key":"10.1016\/j.nrl.2015.03.005_bib0680","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.seizure.2007.12.003","article-title":"Central nervous system adverse effects of new antiepileptic drugs. A meta-analysis of placebo-controlled studies","volume":"17","author":"Zaccara","year":"2008","journal-title":"Seizure."},{"key":"10.1016\/j.nrl.2015.03.005_bib0685","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1111\/j.1528-1167.2010.02966.x","article-title":"The adverse event profile of pregabalin: A systematic review and meta-analysis of randomized controlled trials","volume":"52","author":"Zaccara","year":"2011","journal-title":"Epilepsia."},{"key":"10.1016\/j.nrl.2015.03.005_bib0690","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1111\/ene.12170","article-title":"The adverse event profile of perampanel: Meta-analysis of randomized controlled trials","volume":"20","author":"Zaccara","year":"2013","journal-title":"Eur J Neurol."},{"key":"10.1016\/j.nrl.2015.03.005_bib0695","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.seizure.2013.03.016","article-title":"Neurological adverse events of new generation sodium blocker antiepileptic drugs. Meta-analysis of randomized, double-blinded studies with eslicarbazepine acetate, lacosamide and oxcarbazepine","volume":"22","author":"Zaccara","year":"2013","journal-title":"Seizure."},{"key":"10.1016\/j.nrl.2015.03.005_bib0700","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1111\/j.1528-1167.2012.03589.x","article-title":"The adverse event profile of lacosamide: A systematic review and meta-analysis of randomized controlled trials","volume":"54","author":"Zaccara","year":"2013","journal-title":"Epilepsia."},{"key":"10.1016\/j.nrl.2015.03.005_bib0705","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1212\/01.wnl.0000345667.45642.61","article-title":"Adverse antiepileptic drug effects. Toward a clinically and neurobiologically relevant taxonomy","volume":"72","author":"Perucca","year":"2009","journal-title":"Neurology."},{"key":"10.1016\/j.nrl.2015.03.005_bib0710","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1111\/j.1528-1157.1999.tb05561.x","article-title":"New antiepileptic drugs: Comparison of key clinical trials","volume":"40","author":"Cramer","year":"1999","journal-title":"Epilepsia."},{"key":"10.1016\/j.nrl.2015.03.005_bib0715","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1056\/NEJM200002033420503","article-title":"Early identification of refractory epilepsy","volume":"342","author":"Kwan","year":"2000","journal-title":"N Engl J Med."},{"issue":"Suppl 4","key":"10.1016\/j.nrl.2015.03.005_bib0720","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1212\/WNL.63.10_suppl_4.S9","article-title":"Tolerability of antiseizure medications. Implications for health outcomes","volume":"63","author":"Gilliam","year":"2004","journal-title":"Neurology."},{"key":"10.1016\/j.nrl.2015.03.005_bib0725","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.seizure.2013.11.009","article-title":"Side-effects of antiepileptic drugs: The economic burden","volume":"23","author":"De Kinderen","year":"2014","journal-title":"Seizure."},{"key":"10.1016\/j.nrl.2015.03.005_bib0730","doi-asserted-by":"crossref","unstructured":"Madian AG, Baker Jones R. Variable drug response: Genetic evaluation. En: Cooper DN, editor. Encyclopedia of Life Sciences (eLS). Genetics & Disease. Chichester: John Wiley & Sons Ltd;2013. [consultado 3 Abr 2015]. Disponible en: http:\/\/www.els.net doi: 10.1002\/9780470015902.a0006001.pub2","DOI":"10.1002\/9780470015902.a0006001.pub2"},{"key":"10.1016\/j.nrl.2015.03.005_bib0735","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1056\/NEJMra020526","article-title":"Pharmacogenomics-drug disposition, drug targets and side effects","volume":"348","author":"Evans","year":"2003","journal-title":"N Engl J Med."},{"key":"10.1016\/j.nrl.2015.03.005_bib0740","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1097\/00008571-199808000-00001","article-title":"Hypothesis: Comparisons of inter- and intra-individual variations can substitute for twin studies in drug research","volume":"8","author":"Kalow","year":"1998","journal-title":"Pharmacogenetics."},{"key":"10.1016\/j.nrl.2015.03.005_bib0745","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1056\/NEJMra020021","article-title":"Inheritance and drug response","volume":"348","author":"Weisenhilboum","year":"2003","journal-title":"N Engl J Med."},{"key":"10.1016\/j.nrl.2015.03.005_bib0750","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1111\/j.1528-1167.2007.01041.x","article-title":"Idiosyncratic adverse reactions to antiepielptic drugs","volume":"48","author":"Zaccara","year":"2007","journal-title":"Epilepsia."},{"issue":"Suppl 4","key":"10.1016\/j.nrl.2015.03.005_bib0755","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1212\/WNL.63.10_suppl_4.S3","article-title":"Pharmacogenetics and enzyme induction\/inhibition properties of antiepileptic drugs","volume":"63","author":"Anderson","year":"2004","journal-title":"Neurology."},{"key":"10.1016\/j.nrl.2015.03.005_bib0760","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1038\/sj.tpj.6500278","article-title":"Lower frequency of CYP2 C9*2 in Mexican-Americans compared to Spaniards","volume":"4","author":"Llerena","year":"2004","journal-title":"Pharmacogenomics J."},{"key":"10.1016\/j.nrl.2015.03.005_bib0765","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1097\/00008571-199608000-00007","article-title":"The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism","volume":"6","author":"Sullivan-Klose","year":"1996","journal-title":"Pharmacogenetics."},{"key":"10.1016\/j.nrl.2015.03.005_bib0770","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/tpj.2010.29","article-title":"CYP2C9 allele frequency differences between populations of Mexican-Mestizo, Mexican-Tepehuano, and Spaniards","volume":"11","author":"Dorado","year":"2011","journal-title":"Pharmacogenomics J."},{"key":"10.1016\/j.nrl.2015.03.005_bib0775","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1038\/tpj.2012.52","article-title":"Influence of admixture components on CYP2C9*2 allele frequency in eight indigenous populations from Northwest Mexico","volume":"13","author":"Sosa-Mac\u00edas","year":"2013","journal-title":"Pharmacogenomics J."},{"key":"10.1016\/j.nrl.2015.03.005_bib0780","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1124\/mol.60.2.382","article-title":"Identification and functional characterization of a new CYP2C9 variant (CYP2C9*5) expressed among African Americans","volume":"60","author":"Dickmann","year":"2001","journal-title":"Mol Pharmacol."},{"key":"10.1016\/j.nrl.2015.03.005_bib0785","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1097\/00008571-200112000-00008","article-title":"Identification of a null allele of CYP2C9 in an African-American exhibiting toxicity to phenytoin","volume":"11","author":"Kidd","year":"2001","journal-title":"Pharmacogenetics."},{"key":"10.1016\/j.nrl.2015.03.005_bib0790","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1111\/j.1468-1331.2011.03361.x","article-title":"A candidate gene study of antiepileptic drug tolerability and efficacy identifies an association of CYP2C9 variants with phenytoin toxicity","volume":"18","author":"Depondt","year":"2011","journal-title":"Eur J Neurol."},{"key":"10.1016\/j.nrl.2015.03.005_bib0795","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/tpj.2012.19","article-title":"Neurological toxicity after phenytoin infusion in a pediatric patient with epilepsy: influence of CYP2C9 CYP2 C19 and ABCB1 genetic polymorphisms","volume":"13","author":"Dorado","year":"2013","journal-title":"Pharmacogenomics J."},{"key":"10.1016\/j.nrl.2015.03.005_bib0800","doi-asserted-by":"crossref","first-page":"237","DOI":"10.4103\/0975-7406.116828","article-title":"Charles C Cytochrome P450 2C9 gene polymorphism in phenytoin induced gingival enlargement: A case report","volume":"5","author":"Babu","year":"2013","journal-title":"J Pharm Bioallied Sci."},{"key":"10.1016\/j.nrl.2015.03.005_bib0805","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1097\/00007691-200004000-00016","article-title":"Genetic polymorphism of the CYP2C subfamily and excessive serum phenytoin concentration with central nervous system intoxication","volume":"22","author":"Ninomiya","year":"2000","journal-title":"Ther Drug Monit."},{"key":"10.1016\/j.nrl.2015.03.005_bib0810","doi-asserted-by":"crossref","first-page":"408","DOI":"10.4103\/0028-3886.33300","article-title":"Severe phenytoin toxicity in a CYP2 C9*3*3 homozygous mutant from India","volume":"55","author":"Ramasamy","year":"2007","journal-title":"Neurol India."},{"key":"10.1016\/j.nrl.2015.03.005_bib0815","unstructured":"Pharmgkb Dutch Pharmacogenetics working group guideline for phenytoin and CYP2C9 (2011) [consultado 7 Jun 2014]. Disponible en: http:\/\/www.pharmgkb.org\/guideline\/PA166104984"},{"key":"10.1016\/j.nrl.2015.03.005_bib0820","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1046\/j.0306-5251.2001.01499.x","article-title":"Clinical relevance of genetic polymorphisms in the human CYP2C subfamily","volume":"52","author":"Goldstein","year":"2001","journal-title":"Br J Clin Pharmacol."},{"key":"10.1016\/j.nrl.2015.03.005_bib0825","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1111\/j.1528-1157.1998.tb01330.x","article-title":"The effects of genetic polymorphisms of CYP2C9 and CYP2 C19 on phenytoin metabolism in Japanese adult patients with epilepsy: Studies in stereoselective hydroxylation and population pharmacokinetics","volume":"39","author":"Mamiya","year":"1998","journal-title":"Epilepsia."},{"key":"10.1016\/j.nrl.2015.03.005_bib0830","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1097\/FPC.0b013e32834aeedb","article-title":"PharmGKB summary: Phenytoin pathway","volume":"22","author":"Thorn","year":"2012","journal-title":"Pharmacogenet Genomics."},{"key":"10.1016\/j.nrl.2015.03.005_bib0835","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1002\/bdrc.20098","article-title":"Effects of oxidative stress on embryonic development","volume":"81","author":"Dennery","year":"2007","journal-title":"Birth Defect Res C Embryo Today."},{"key":"10.1016\/j.nrl.2015.03.005_bib0840","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1097\/FPC.0b013e328334b6a3","article-title":"Maternal EPHX1 polymorphisms and risk of phenytoin-induced congenital malformations","volume":"20","author":"Azzato","year":"2010","journal-title":"Pharmacogenet Genomics."},{"key":"10.1016\/j.nrl.2015.03.005_bib0845","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/BF03256188","article-title":"Carbamazepine-provoked hepatotoxicity and possible aetiopathological role of glutathione in the events. Retrospective review of old data and call for new investigation","volume":"21","author":"Kalapos","year":"2002","journal-title":"Adverse Drug React Toxicol Rev."},{"key":"10.1016\/j.nrl.2015.03.005_bib0850","doi-asserted-by":"crossref","first-page":"435","DOI":"10.2217\/14622416.8.5.435","article-title":"Glutathione S-transferase M1 null genotype as a risk factor for carbamazepine-induced mild hepatotoxicity","volume":"8","author":"Ueda","year":"2007","journal-title":"Pharmacogenomics."},{"issue":"1-2","key":"10.1016\/j.nrl.2015.03.005_bib0855","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.cca.2007.11.035","article-title":"Glutathione-S-transferase (GST) M1 null genotype and combined GSTM1 and GSTT1 null genotypes are risk factors for increased serum (-glutamyltransferase in valproic acid-treated patients","volume":"389","author":"Fukushima","year":"2008","journal-title":"Clin Chim Acta."},{"key":"10.1016\/j.nrl.2015.03.005_bib0860","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1038\/sj.tpj.6500171","article-title":"Pharmacogenomics of human UDP glucuronosyltransferase enzymes","volume":"3","author":"Guillemette","year":"2003","journal-title":"Pharmacogenomics J."},{"key":"10.1016\/j.nrl.2015.03.005_bib0865","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.3390\/ph3082709","article-title":"Update on the genetic polymorphisms of drug-metabolizing enzymes in antiepileptic drug therapy","volume":"3","author":"Saruwatari","year":"2010","journal-title":"Pharmaceuticals."},{"issue":"1-2","key":"10.1016\/j.nrl.2015.03.005_bib0870","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.eplepsyres.2011.01.016","article-title":"The relationship between UGT1 A4 polymorphism and serum concentration of lamotrigine in patients with epilepsy","volume":"95","author":"Gulcebi","year":"2011","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.nrl.2015.03.005_bib0875","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1007\/s00228-012-1277-7","article-title":"Influence of UDP-glucuronosyltransferase polymorphisms on valproic acid pharmacokinetics in Chinese epilepsy patients","volume":"68","author":"Chu","year":"2012","journal-title":"Eur J Clin Pharmacol."},{"key":"10.1016\/j.nrl.2015.03.005_bib0880","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/s40291-013-0041-8","article-title":"The effect of uridine diphosphate glucuronosyltransferase (UGT)1 A6 genetic polymorphism on valproic acid pharmacokinetics in Indian patients with epilepsy: A pharmacogenetic approach","volume":"17","author":"Munisamy","year":"2013","journal-title":"Mol Diagn Ther."},{"key":"10.1016\/j.nrl.2015.03.005_bib0885","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1007\/s00018-003-3336-9","article-title":"The ABC transporter structure and mechanism: Perspectives on recent research","volume":"61","author":"Jones","year":"2004","journal-title":"Cell Mol Life Sci."},{"key":"10.1016\/j.nrl.2015.03.005_bib0890","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1046\/j.1528-1157.2001.12301.x","article-title":"Overexpression of multiple drug resistance genes in endothelial cells from patients with refractory epilepsy","volume":"42","author":"Dombrowski","year":"2001","journal-title":"Epilepsia."},{"key":"10.1016\/j.nrl.2015.03.005_bib0895","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1124\/jpet.103.049858","article-title":"Multidrug resistance protein MRP2 contributes to blood-brain barrier function and restricts antiepileptic drug activity","volume":"306","author":"Potschka","year":"2003","journal-title":"J Pharmacol Exp Ther."},{"key":"10.1016\/j.nrl.2015.03.005_bib0900","doi-asserted-by":"crossref","first-page":"254","DOI":"10.5808\/GI.2013.11.4.254","article-title":"Genetic variations of ABCC2 gene associated with adverse drug reactions to valproic acid in Korean epileptic patients","volume":"11","author":"Yi","year":"2013","journal-title":"Genomics Inform."},{"key":"10.1016\/j.nrl.2015.03.005_bib0905","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.eplepsyres.2008.12.001","article-title":"Lack of association between ABCB1, ABCG2 and ABCC2 genetic polymorphisms and multidrug resistance in partial epilepsy","volume":"84","author":"Kim","year":"2009","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.nrl.2015.03.005_bib0910","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1211\/jpp.60.5.0009","article-title":"ABCC2 haplotype is not associated with drug-resistant epilepsy","volume":"60","author":"Seo","year":"2008","journal-title":"J Pharm Pharmacol."},{"key":"10.1016\/j.nrl.2015.03.005_bib0915","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1097\/FPC.0b013e328338073a","article-title":"A nonsynonymous variation in MRP2\/ABCC2 is associated with neurological adverse drug reactions of carbamazepine in patients with epilepsy","volume":"20","author":"Kim","year":"2010","journal-title":"Pharmacogenet Genomics."},{"key":"10.1016\/j.nrl.2015.03.005_bib0920","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1097\/01.fpc.0000236337.41799.b3","article-title":"MRP2 haplotypes confer differential susceptibility to toxic liver injury","volume":"17","author":"Choi","year":"2007","journal-title":"Pharmacogenet Genomics."},{"key":"10.1016\/j.nrl.2015.03.005_bib0925","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1016\/j.neuropharm.2008.08.032","article-title":"Several major antiepileptic drugs are substrates for human P-glycoprotein","volume":"55","author":"Luna-Tort\u00f3s","year":"2008","journal-title":"Neuropharmacology."},{"key":"10.1016\/j.nrl.2015.03.005_bib0930","doi-asserted-by":"crossref","first-page":"3473","DOI":"10.1073\/pnas.97.7.3473","article-title":"Functional polymorphisms of the human multidrug-resistance gene: Multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo","volume":"97","author":"Hoffmeyer","year":"2000","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.nrl.2015.03.005_bib0935","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1097\/FPC.0b013e3282f85e36","article-title":"Functional evaluation of polymorphisms in the human ABCB1 gene and the impact on clinical responses of antiepileptic drugs","volume":"18","author":"Hung","year":"2008","journal-title":"Pharmacogenet Genomics."},{"key":"10.1016\/j.nrl.2015.03.005_bib0940","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S1474-4422(06)70352-0","article-title":"Update on pharmacogenetics in epilepsy: A brief review","volume":"5","author":"Szoeke","year":"2006","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.nrl.2015.03.005_bib0945","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1056\/NEJMcp1104080","article-title":"Exanthematous drug eruptions","volume":"366","author":"Stern","year":"2012","journal-title":"N Engl J Med."},{"key":"10.1016\/j.nrl.2015.03.005_bib0950","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1056\/NEJMoa1013297","article-title":"HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans","volume":"364","author":"McCormack","year":"2011","journal-title":"N Engl J Med."},{"key":"10.1016\/j.nrl.2015.03.005_bib0955","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1001\/archderm.145.1.67","article-title":"Twelve-year analysis of severe cases of drug reaction with eosinophilia and systemic symptoms. A cause of unpredictable multiorgan failure","volume":"145","author":"Eshki","year":"2009","journal-title":"Arch Dermatol."},{"key":"10.1016\/j.nrl.2015.03.005_bib0960","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2332\/allergolint.55.1","article-title":"Drug-induced hypersensitivity syndrome (DIHS): A reaction induced by a complex interplay among herpesviruses and antiviral and antidrug immune responses","volume":"55","author":"Shiohara","year":"2006","journal-title":"Allergol Int."},{"key":"10.1016\/j.nrl.2015.03.005_bib0965","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1111\/j.1346-8138.2010.01196.x","article-title":"Pharmacogenetics of cutaneous adverse drug reactions","volume":"38","author":"Aihara","year":"2011","journal-title":"J Dermatol."},{"key":"10.1016\/j.nrl.2015.03.005_bib0970","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/0895-4356(96)00035-2","article-title":"Epidemiology of erythema exsudativum multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis in Germany (1990-1992): Structure and results of a population-based registry","volume":"49","author":"Rzany","year":"1996","journal-title":"J Clin Epidemol."},{"key":"10.1016\/j.nrl.2015.03.005_bib0975","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1001\/archderm.1993.01680220104023","article-title":"Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme","volume":"129","author":"Bastuji-Garin","year":"1993","journal-title":"Arch Dermatol."},{"key":"10.1016\/j.nrl.2015.03.005_bib0980","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1111\/j.1346-8138.1997.tb02524.x","article-title":"Stevens-Johnson syndrome and toxic epidermal necrolysis are severity variants of the same disease which differs from erythema multiforme","volume":"24","author":"Roujeau","year":"1997","journal-title":"J Dermatol."},{"key":"10.1016\/j.nrl.2015.03.005_bib0985","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1097\/BCR.0b013e3181a28c82","article-title":"Toxic epidermal necrolysis in children: Medical surgical, and ophthalmologic considerations","volume":"30","author":"Goyal","year":"2009","journal-title":"J Burn Care Res."},{"key":"10.1016\/j.nrl.2015.03.005_bib0990","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1159\/000070938","article-title":"Dermatological and ophthalmological sequels in toxic epidermal necrolysis","volume":"207","author":"Magina","year":"2003","journal-title":"Dermatol."},{"key":"10.1016\/j.nrl.2015.03.005_bib0995","doi-asserted-by":"crossref","first-page":"268","DOI":"10.4065\/84.3.268","article-title":"Mechanisms of drug-induced allergy","volume":"84","author":"Schnyder","year":"2009","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.nrl.2015.03.005_bib1000","doi-asserted-by":"crossref","first-page":"483","DOI":"10.2165\/00002018-200023060-00002","article-title":"Immunological principles of adverse drug reactions: The initiation and propagation of immune responses elicited by drug treatment","volume":"23","author":"Naisbitt","year":"2000","journal-title":"Drug Safety."},{"key":"10.1016\/j.nrl.2015.03.005_bib1005","doi-asserted-by":"crossref","first-page":"17","DOI":"10.2332\/allergolint.55.17","article-title":"Pharmacological interaction of drugs with immune receptors: The p-i concept","volume":"55","author":"Pichler","year":"2006","journal-title":"Allergol Int"},{"key":"10.1016\/j.nrl.2015.03.005_bib1010","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1016\/j.molimm.2007.07.042","article-title":"HLA class i and class ii haplotypes in admixed families from several regions of Mexico","volume":"45","author":"Barquera","year":"2008","journal-title":"Mol Immunol"},{"key":"10.1016\/j.nrl.2015.03.005_bib1015","series-title":"Gen\u00e9tica cl\u00ednica","first-page":"445","article-title":"Inmunogen\u00e9tica del complejo principal de histocompatibilidad","author":"Granados-Arriola","year":"2012"},{"key":"10.1016\/j.nrl.2015.03.005_bib1020","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/428486a","article-title":"Medical genetics: A marker for Stevens-Johnson syndrome","volume":"428","author":"Chung","year":"2004","journal-title":"Nature."},{"key":"10.1016\/j.nrl.2015.03.005_bib1025","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1097\/01.fpc.0000199500.46842.4a","article-title":"Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions","volume":"16","author":"Hung","year":"2006","journal-title":"Pharmacogenet Genom."},{"key":"10.1016\/j.nrl.2015.03.005_bib1030","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1111\/j.1528-1167.2007.01022.x","article-title":"Association between HLA-B*1502 allele and antiepileptic drug-induced cutaneous reactions in Han Chinese","volume":"48","author":"Man","year":"2007","journal-title":"Epilepsia."},{"key":"10.1016\/j.nrl.2015.03.005_bib1035","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.eplepsyres.2011.02.005","article-title":"Influence of chemical structure on skin reactions induced by antiepileptic drugs \u2014The role of the aromatic ring","volume":"94","author":"Wang","year":"2011","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.nrl.2015.03.005_bib1040","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1001\/jamadermatol.2013.4114","article-title":"Relationship between the HLA-B*1502 allele and carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"149","author":"Tangamornsukan","year":"2013","journal-title":"JAMA Dermatol."},{"key":"10.1016\/j.nrl.2015.03.005_bib1045","unstructured":"Carbamazepine (marketed as carbatrol, equetro, tegreto and generics) FDA, US Food and Drug Administration. 2007 [consultado 7 Jun 2014]. Disponible en: http:\/\/www.fda.gov\/Safety\/MedWatch\/SafetyInformation\/SafetyAlertsforHumanMedicalProducts\/ucm150841.htm"},{"key":"10.1016\/j.nrl.2015.03.005_bib1050","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/sj.tpj.6500356","article-title":"A marker for Stevens-Johnson syndrome\u2026: Ethnicity matters","volume":"6","author":"Lonjou","year":"2006","journal-title":"Pharmacogenomics J."},{"key":"10.1016\/j.nrl.2015.03.005_bib1055","first-page":"550","article-title":"HLA class i and ii gene polymorphisms in Stevens-Johnson syndrome with ocular complications in Japanese","volume":"14","author":"Ueta","year":"2008","journal-title":"Mol Vis."},{"key":"10.1016\/j.nrl.2015.03.005_bib1060","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1111\/j.1528-1167.2010.02766.x","article-title":"HLA-B*1511 is a risk factor for carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in japanese patients","volume":"51","author":"Kaniwa","year":"2010","journal-title":"Epilepsia."},{"key":"10.1016\/j.nrl.2015.03.005_bib1065","doi-asserted-by":"crossref","first-page":"399","DOI":"10.2217\/pgs.11.165","article-title":"Genome-wide mapping for clinically relevant predictors of lamotrigine- and phenytoin-induced hypersensitivity reactions","volume":"13","author":"McCormack","year":"2012","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.nrl.2015.03.005_bib1070","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1093\/hmg\/ddq537","article-title":"Genome-wide association study identifies HLA-A*3101 allele as a genetic risk factor for carbamazepine-induced cutaneous adverse drug reactions in Japanese population","volume":"20","author":"Ozeki","year":"2011","journal-title":"Hum Mol Genet."},{"issue":"1-2","key":"10.1016\/j.nrl.2015.03.005_bib1075","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.eplepsyres.2013.05.004","article-title":"Predictive markers for carbamazepine and lamotrigine-induced maculopapular exanthema in Han Chinese","volume":"106","author":"Li","year":"2013","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.nrl.2015.03.005_bib1080","doi-asserted-by":"crossref","first-page":"349","DOI":"10.2217\/pgs.09.162","article-title":"Common risk allele in aromatic antiepileptic-drug induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Han Chinese","volume":"11","author":"Hung","year":"2010","journal-title":"Pharmacogenomics."},{"key":"10.1016\/j.nrl.2015.03.005_bib1085","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1212\/WNL.56.7.890","article-title":"TNFalpha promoter region gene polymorphisms in carbamazepine-hypersensitive patients","volume":"56","author":"Pirmohamed","year":"2001","journal-title":"Neurology."},{"key":"10.1016\/j.nrl.2015.03.005_bib1090","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1111\/j.1528-1167.2009.02269.x","article-title":"HLA Class I markers in Japanese patients with carbamazepine-induced cutaneous adverse reactions","volume":"51","author":"Ikeda","year":"2010","journal-title":"Epilepsia."}],"container-title":["Neurolog\u00eda"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0213485315000560?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0213485315000560?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T23:05:21Z","timestamp":1748387121000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0213485315000560"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4]]},"references-count":109,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,4]]}},"alternative-id":["S0213485315000560"],"URL":"https:\/\/doi.org\/10.1016\/j.nrl.2015.03.005","relation":{},"ISSN":["0213-4853"],"issn-type":[{"value":"0213-4853","type":"print"}],"subject":[],"published":{"date-parts":[[2018,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Farmacogen\u00e9tica de reacciones adversas a f\u00e1rmacos antiepil\u00e9pticos","name":"articletitle","label":"Article Title"},{"value":"Neurolog\u00eda","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nrl.2015.03.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2014 Sociedad Espa\u00f1ola de Neurolog\u00eda. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}]}}